Sapacitabine

Sapacitabine may therefore be of particular benefit to patients with ATM-defective blood cancers.

unknown title 2011

Sapacitabine acts through a dual mechanism, interfering with DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell cycle progression mainly at G2-Phase.

unknown title 2011

Sapacitabine CYC682, a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer.

unknown title 2011

Sapacitabine CYC682, an orally-available nucleoside analogue, is currently being evaluated in a registration-directed, Phase 3 trial in front-line elderly AML and Phase 2 trials in patients with hematological malignancies and solid tumors.

unknown title 2011

Sapacitabine CYC682, a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia.

unknown title 2011

Sapacitabine is part of Cyclacel's pipeline of small molecule drugs designed to target and stop uncontrolled cell division.

unknown title 2011

Sapacitabine CYC682, a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer.

unknown title 2011

Sapacitabine has been administered to approximately 170 patients in five Phase 1 studies with both hematological malignancies and solid tumors.

unknown title 2011

Sapacitabine may be of particular benefit to patients with ATM-defective leukemia cells.

unknown title 2011

Sapacitabine CYC682, an orally-available nucleoside analog, will be entering Phase 3

Publications Highlight Novel Combinations of Sapacitabine With Targeted Agents for the Treatment of Cancer - Yahoo! Finance 2010